This study has tested whether phentonium bromide, a quaternary ammonium anti-muscarinic agent, could reverse the signs of precipitated opioid withdrawal. Rats were treated with either saline or morphine for 4 days, after which half the rats received naloxone and half saline. Each animal also received one of four doses of phentonium bromide (0, 1, 3 and 9 mg kg(-1), i.p.). Administration of phentonium bromide in rats receiving naloxone after chronic morphine treatment reduced the intensity of withdrawal signs such as increased defecation or micturition, salivation and wet-dog shakes, and elevated the nociceptive threshold values. The effects of administration of phentonium bromide might result from its anti-muscarinic activity interfering peripherally with the mechanisms involved in the regulation of the withdrawal symptoms. The use of this drug is thus suggested as a possible means of controlling some of the signs observed during the acute phase of opioid withdrawal in heroin addicts.
Effects of administration of phentonium bromide on opioid withdrawal syndrome in rats / A. Pinelli, S. Trivulzio, L. Tomasoni. - In: JOURNAL OF PHARMACY AND PHARMACOLOGY. - ISSN 0022-3573. - 49:12(1997 Dec), pp. 1222-1228.
|Titolo:||Effects of administration of phentonium bromide on opioid withdrawal syndrome in rats|
PINELLI, ARNALDO (Primo)
TRIVULZIO, SILVIO GIUSEPPE (Secondo)
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||dic-1997|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/j.2042-7158.1997.tb06074.x|
|Appare nelle tipologie:||01 - Articolo su periodico|